457 related articles for article (PubMed ID: 26033801)
21. Is Microscopic Vascular Invasion in Tumor Specimens Associated with Worse Prognosis in Patients with High-grade Localized Osteosarcoma?
Tsuda Y; Tsoi K; Stevenson JD; Parry MC; Fujiwara T; Sumathi V; Jeys LM
Clin Orthop Relat Res; 2020 Jun; 478(6):1190-1198. PubMed ID: 31904683
[TBL] [Abstract][Full Text] [Related]
22. A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy.
Navid F; Santana VM; Neel M; McCarville MB; Shulkin BL; Wu J; Billups CA; Mao S; Daryani VM; Stewart CF; Kunkel M; Smith W; Ward D; Pappo AS; Bahrami A; Loeb DM; Reikes Willert J; Rao BN; Daw NC
Int J Cancer; 2017 Oct; 141(7):1469-1477. PubMed ID: 28631382
[TBL] [Abstract][Full Text] [Related]
23. Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.
Gaspar N; Occean BV; Pacquement H; Bompas E; Bouvier C; Brisse HJ; Castex MP; Cheurfa N; Corradini N; Delaye J; Entz-Werlé N; Gentet JC; Italiano A; Lervat C; Marec-Berard P; Mascard E; Redini F; Saumet L; Schmitt C; Tabone MD; Verite-Goulard C; Le Deley MC; Piperno-Neumann S; Brugieres L; ; ;
Eur J Cancer; 2018 Jan; 88():57-66. PubMed ID: 29190507
[TBL] [Abstract][Full Text] [Related]
24. Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas?
Fan Z; Patel S; Lewis VO; Guadagnolo BA; Lin PP
Clin Orthop Relat Res; 2015 Nov; 473(11):3604-11. PubMed ID: 26197952
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan.
Kudawara I; Aoki Y; Ueda T; Araki N; Naka N; Nakanishi H; Matsumine A; Ieguchi M; Mori S; Myoui A; Kuratsu S; Hashimoto N; Yoshikawa H
J Chemother; 2013 Feb; 25(1):41-8. PubMed ID: 23433444
[TBL] [Abstract][Full Text] [Related]
26. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
Piperno-Neumann S; Le Deley MC; Rédini F; Pacquement H; Marec-Bérard P; Petit P; Brisse H; Lervat C; Gentet JC; Entz-Werlé N; Italiano A; Corradini N; Bompas E; Penel N; Tabone MD; Gomez-Brouchet A; Guinebretière JM; Mascard E; Gouin F; Chevance A; Bonnet N; Blay JY; Brugières L; ; ;
Lancet Oncol; 2016 Aug; 17(8):1070-1080. PubMed ID: 27324280
[TBL] [Abstract][Full Text] [Related]
27. Marginal resection for osteosarcoma with effective neoadjuvant chemotherapy: long-term outcomes.
Xu M; Xu S; Yu X
World J Surg Oncol; 2014 Nov; 12():341. PubMed ID: 25391880
[TBL] [Abstract][Full Text] [Related]
28. Histologic Response and Toxicity following Interval-Compressed Four-Drug Therapy Given Preoperatively in Children and Young Adults with Osteosarcoma: A Retrospective Study.
Kang JM; Ju HY; Joo J; Sung JY; Park SY; Kim JH; Kang HG; Kwon M; Park M; Park HJ; Park BK
Oncology; 2020; 98(2):81-90. PubMed ID: 31509843
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.
Eggermont AM; Suciu S; Santinami M; Testori A; Kruit WH; Marsden J; Punt CJ; Salès F; Gore M; MacKie R; Kusic Z; Dummer R; Hauschild A; Musat E; Spatz A; Keilholz U;
Lancet; 2008 Jul; 372(9633):117-126. PubMed ID: 18620949
[TBL] [Abstract][Full Text] [Related]
30. Risk-Based Therapy for Localized Osteosarcoma.
Venkatramani R; Murray J; Helman L; Meyer W; Hicks MJ; Krance R; Lau C; Jo E; Chintagumpala M
Pediatr Blood Cancer; 2016 Mar; 63(3):412-7. PubMed ID: 26501936
[TBL] [Abstract][Full Text] [Related]
31. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma.
Schmidt J; Abel U; Debus J; Harig S; Hoffmann K; Herrmann T; Bartsch D; Klein J; Mansmann U; Jäger D; Capussotti L; Kunz R; Büchler MW
J Clin Oncol; 2012 Nov; 30(33):4077-83. PubMed ID: 23008325
[TBL] [Abstract][Full Text] [Related]
32. Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing's Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 Trial.
Andreou D; Ranft A; Gosheger G; Timmermann B; Ladenstein R; Hartmann W; Bauer S; Baumhoer D; van den Berg H; Dijkstra PDS; Dürr HR; Gelderblom H; Hardes J; Hjorth L; Kreyer J; Kruseova J; Leithner A; Scobioala S; Streitbürger A; Tunn PU; Wardelmann E; Windhager R; Jürgens H; Dirksen U;
Clin Orthop Relat Res; 2020 Feb; 478(2):290-302. PubMed ID: 31580267
[TBL] [Abstract][Full Text] [Related]
33. Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response.
Ferrari S; Mercuri M; Picci P; Bertoni F; Brach del Prever A; Tienghi A; Mancini A; Longhi A; Rimondini S; Donati D; Manfrini M; Ruggieri P; Biagini R; Bacci G
Tumori; 1999; 85(6):458-64. PubMed ID: 10774566
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide.
Bacci G; Briccoli A; Rocca M; Ferrari S; Donati D; Longhi A; Bertoni F; Bacchini P; Giacomini S; Forni C; Manfrini M; Galletti S
Ann Oncol; 2003 Jul; 14(7):1126-34. PubMed ID: 12853357
[TBL] [Abstract][Full Text] [Related]
35. Analysis of chemotherapy dosage and dosage intensity and survival outcomes of high-grade osteosarcoma patients younger than 40 years.
Sun L; Li Y; Li H; Zhang J; Li B; Ye Z
Clin Ther; 2014 Apr; 36(4):567-78. PubMed ID: 24636527
[TBL] [Abstract][Full Text] [Related]
36. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol.
Meyers PA; Gorlick R; Heller G; Casper E; Lane J; Huvos AG; Healey JH
J Clin Oncol; 1998 Jul; 16(7):2452-8. PubMed ID: 9667263
[TBL] [Abstract][Full Text] [Related]
37. Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk Melanoma.
Navid F; Herzog CE; Sandoval J; Daryani VM; Stewart CF; Gattuso J; Mandrell B; Phipps S; Chemaitilly W; Sykes A; Davidoff AM; Shulkin BL; Bahrami A; Furman WL; Mao S; Wu J; Schiff D; Rao B; Pappo A
Pediatr Blood Cancer; 2016 Jul; 63(7):1207-13. PubMed ID: 27038395
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial.
Eggermont AMM; Rutkowski P; Dutriaux C; Hofman-Wellenhof R; Dziewulski P; Marples M; Grange F; Lok C; Pennachioli E; Robert C; van Akkooi ACJ; Bastholt L; Minisini A; Marshall E; Salès F; Grob JJ; Bechter O; Schadendorf D; Marreaud S; Kicinski M; Suciu S; Testori AAE
Eur J Cancer; 2020 Jul; 133():94-103. PubMed ID: 32470710
[TBL] [Abstract][Full Text] [Related]
40. p16 expression as a prognostic and predictive marker in high-grade localized osteosarcoma of the extremities: an analysis of 357 cases.
Righi A; Gambarotti M; Sbaraglia M; Sisto A; Ferrari S; Dei Tos AP; Picci P
Hum Pathol; 2016 Dec; 58():15-23. PubMed ID: 27544803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]